Nobel winner Demis Hassabis talks next steps for AI in biology
LONDON — Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic Labs over the past three years. In an exclusive sitdown ...
View ArticleDenali teases early data for enzyme replacement therapy in rare disease
Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an enzyme replacement therapy for...
View ArticleGeron’s royalty deal; Minghui’s new VEGF bispecific data
Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal with Royalty Pharma based on ...
View ArticleAurinia cuts nearly half of its workforce in second round of layoffs this year
Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company announced the layoffs on ...
View ArticleGenmab chops early cancer prospects to prioritize Phase 3 projects
Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ADC from its purchase of ProfoundBio. After “careful consideration,” Genmab...
View ArticleCoherus restarts biosimilar supply after delays; Novavax ends Covid vaccine...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its Neulasta biosimilar after...
View ArticleFDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy
After 17 years of back and forth with citizen petitions and two advisory committees, the FDA on Thursday proposed to pull commonly-used nasal decongestant active ingredients in common over-the-counter...
View ArticleVaccine makers face headwinds from RFK, soft demand and China
Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new products and a new impetus to prevent infections. But just a few years...
View ArticleStephen Squinto's JPM life sciences team is raising a new fund for...
CHICAGO — Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a second fund geared toward more growth-stage opportunities. ...
View ArticleSenior AstraZeneca exec detained in China amid wider investigation
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his detainment, Leon Wang, executive vice president of international and president...
View ArticlePfizer to invest $1B in China over next five years — reports
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a new phase of growth. Pfizer China President Jean-Christophe Pointeau said ...
View ArticleNkarta drops another cancer program as it leans into autoimmune disease
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects in autoimmune disease. The biotech will stop investigating NKX019 in...
View ArticleLegend names a president of Carvykti; Novo Nordisk's top North America exec...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the commercial future of the biotech's sole marketed cell therapy, among other...
View ArticleBenevolentAI co-founder returns with plan to save drug developer
Can Ken Mulvany save BenevolentAI? About a decade ago, Mulvany helped found the company as part of the first generation of AI-focused biotech startups. It soared to a $2 billion valuation, pitching a...
View ArticleDaiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode deal
Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the...
View ArticleEisai slashes Leqembi sales forecast by almost $100M
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most closely-watched drugs. The company now expects that the Alzheimer's treatment will bring...
View ArticleAmgen and AstraZeneca share positive results in chronic rhinosinusitis
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition....
View Article